Merus (MRUS) Competitors $44.90 +2.10 (+4.91%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MRUS vs. PCVX, CTLT, QGEN, ITCI, ROIV, RVMD, ASND, LEGN, NUVL, and LNTHShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Vaxcyte (PCVX), Catalent (CTLT), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Nuvalent (NUVL), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Merus vs. Vaxcyte Catalent Qiagen Intra-Cellular Therapies Roivant Sciences Revolution Medicines Ascendis Pharma A/S Legend Biotech Nuvalent Lantheus Vaxcyte (NASDAQ:PCVX) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Do institutionals and insiders hold more shares of PCVX or MRUS? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 4.6% of Merus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer PCVX or MRUS? In the previous week, Merus had 6 more articles in the media than Vaxcyte. MarketBeat recorded 12 mentions for Merus and 6 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.00 beat Merus' score of 0.54 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 4 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community prefer PCVX or MRUS? Merus received 309 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 74.58% of users gave Vaxcyte an outperform vote while only 67.11% of users gave Merus an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4474.58% Underperform Votes1525.42% MerusOutperform Votes35367.11% Underperform Votes17332.89% Which has stronger earnings and valuation, PCVX or MRUS? Merus has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-19.53Merus$35.93M85.55-$154.94M-$3.95-11.37 Do analysts recommend PCVX or MRUS? Vaxcyte presently has a consensus target price of $147.50, indicating a potential upside of 64.14%. Merus has a consensus target price of $85.64, indicating a potential upside of 90.73%. Given Merus' stronger consensus rating and higher possible upside, analysts clearly believe Merus is more favorable than Vaxcyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Is PCVX or MRUS more profitable? Vaxcyte has a net margin of 0.00% compared to Merus' net margin of -680.61%. Vaxcyte's return on equity of -23.53% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Merus -680.61%-38.89%-31.16% Which has more risk & volatility, PCVX or MRUS? Vaxcyte has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. SummaryMerus beats Vaxcyte on 12 of the 18 factors compared between the two stocks. Ad Porter & CompanyForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.07B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-11.3710.75135.1817.53Price / Sales85.55287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book7.285.394.884.92Net Income-$154.94M$152.04M$118.97M$225.78M7 Day Performance3.96%-4.32%16.19%-1.58%1 Month Performance1.42%2.80%16.02%6.67%1 Year Performance79.96%17.30%34.95%22.48% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.9299 of 5 stars$44.90+4.9%$85.64+90.7%+77.9%$3.07B$35.93M-11.3737PCVXVaxcyte1.8076 of 5 stars$91.83-1.6%$147.50+60.6%+48.4%$11.45BN/A0.00160CTLTCatalent2.7567 of 5 stars$62.10+0.4%$63.40+2.1%+53.0%$11.27B$4.38B0.0016,900QGENQiagen4.2311 of 5 stars$44.11+1.6%$50.80+15.2%+3.6%$10.07B$1.97B112.265,967ITCIIntra-Cellular Therapies4.1678 of 5 stars$84.35-0.2%$97.23+15.3%+32.9%$8.94B$464.37M0.00560ROIVRoivant Sciences2.667 of 5 stars$12.20-1.3%$17.93+47.0%+8.9%$8.88B$124.79M2.19860Positive NewsRVMDRevolution Medicines4.6632 of 5 stars$46.95-2.3%$63.67+35.6%+69.6%$7.90B$742,000.00-13.33443Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$129.43-2.7%$191.77+48.2%+16.0%$7.85B$288.08M0.00640Short Interest ↑LEGNLegend Biotech1.6722 of 5 stars$42.51+2.3%$81.54+91.8%-43.4%$7.76B$285.14M-44.321,800NUVLNuvalent2.3475 of 5 stars$94.07-0.3%$112.60+19.7%+9.7%$6.68BN/A0.0040Positive NewsLNTHLantheus4.4014 of 5 stars$91.95+3.3%$130.00+41.4%+21.9%$6.39B$1.30B14.81834Positive News Related Companies and Tools Related Companies Vaxcyte Competitors Catalent Competitors Qiagen Competitors Intra-Cellular Therapies Competitors Roivant Sciences Competitors Revolution Medicines Competitors Ascendis Pharma A/S Competitors Legend Biotech Competitors Nuvalent Competitors Lantheus Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRUS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts